SFBC International Announces Opening of Bioanalytical Laboratory in To

    Business Editors/Health Editors

    MIAMI--(BUSINESS WIRE)--Jan. 25, 2005--SFBC International, Inc. (NASDAQ:SFCC), a provider of specialized drug development services to global and specialty pharmaceutical, biotechnology and generic drug companies, announced today that SFBC Anapharm, its wholly-owned subsidiary, has opened a new bioanalytical laboratory at the Company's facility in Toronto.
    The new 10,000 square-foot laboratory is solely devoted to the high-pressure liquid chromatography-tandem mass spectrometry, or LC-MS-MS, technology platform. SFBC invested approximately $4.0 million in capital expenditures, comprised of equipment, software and build out, for this new lab. Cutting-edge robotic instruments will secure a large output in biological sample analysis and will assist SFBC Anapharm in continuing to develop assay methods for the global pharmaceutical, generic drug and biotechnology industries. This laboratory is an extension of SFBC Anapharm's Quebec City bioanalytical laboratory. SFBC currently has bioanalytical laboratories in Quebec City, Quebec; Toronto, Ontario; Philadelphia, PA; Princeton, NJ and Barcelona, Spain.
    Dr. Marc LeBel, President and CEO of SFBC Anapharm, commented, "We are pleased that the new lab in Toronto opened on schedule and we have recently initiated work for our clients at this facility. We look forward to servicing new and existing clients in our Toronto lab. We anticipate that the lab expansion will help meet increasing demand for our bioanalytical services. We believe SFBC's five bioanalytical laboratories that are located throughout North America and Europe are well positioned to capture a larger portion of the bioanalytical laboratory services market."

    About SFBC International, Inc.

    SFBC International, Inc. is a leader in providing early and late stage drug development services to support the growing drug development needs of the pharmaceutical, biotechnology, medical device and generic drug industries around the world. The company has more than 30 offices located in North America, South America, Europe, India, and Australia. SFBC specializes primarily in the areas of Phase I clinical trials and bioanalytical laboratory services, including early clinical pharmacology, and Phase II - IV services worldwide. The company also offers clinical development expertise in the following areas: strategic planning protocol/CRF design, consulting, project management, site selection and management, trial monitoring, information technology including electronic data capture, data management and biostatistics, quality control/assurance, late-stage services and regulatory affairs. Additional information is available at the Company's website, http://www.sfbci.com.

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including the increasing demand for our bioanalytical services and our five laboratories being well positioned to capture more market share. Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; factors which affect the profitability of SFBC's clients, including drug safety issues; our ability to compete internationally in attracting pharmaceutical companies in order to develop additional business; our clients' ability to provide the drugs and medical devices used in our clinical trials; and the economic climate nationally and internationally as it affects drug development operations. Further information on the Company's risk factors is contained in the Company's Form 10-K and other filings with the Securities and Exchange Commission.

--30--CM/mi*

CONTACT: SFBC International, Inc., Miami Ana Lopez, 305-895-0304 or Financial Dynamics Evan Smith, CFA / Erica Pettit, 212-850-5606 / 212-850-5614

KEYWORD: FLORIDA INTERNATIONAL CANADA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL MEDICAL DEVICES BIOTECHNOLOGY SOURCE: SFBC International, Inc.

Copyright Business Wire 2005